27 research outputs found
TLR3-Induced Placental miR-210 Down-Regulates the STAT6/Interleukin-4 Pathway
Several clinical studies have reported increased placental miR-210 expression in women with PE compared to normotensive women, but whether miR-210 plays a role in the etiology of PE is unknown. We reported that activation of TLR3 produces the PE-like symptoms of hypertension, endothelial dysfunction, and proteinuria in mice only when pregnant, but whether TLR3 activation in pregnant mice and human cytotrophoblasts (CTBs) increases miR-210 and modulates its targets related to inflammation are unknown. Placental miR-210 levels were increased significantly in pregnant mice treated with the TLR3 agonist poly I:C (P-PIC). Both HIF-1α and NF-κBp50, known to bind the miR-210 promoter and induce its expression, were also increased significantly in placentas of P-PIC mice. Target identification algorithms and gene ontology predicted STAT6 as an inflammation-related target of miR-210 and STAT6 was decreased significantly in placentas of P-PIC mice. IL-4, which is regulated by STAT6 and increases during normotensive pregnancy, failed to increase in serum of P-PIC mice. P-PIC TLR3 KO mice did not develop hypertension and placental HIF-1α, NF-κBp50, miR-210, STAT6, and IL-4 levels were unchanged. To determine the placental etiology, treatment of human CTBs with poly I:C significantly increased HIF-1α, NF-κBp50, and miR-210 levels and decreased STAT6 and IL-4 levels. Overexpression of miR-210 in CTBs decreased STAT6 and IL-4 while inhibition of miR-210 increased STAT6 and IL-4. These findings demonstrate that TLR3 activation induces placental miR-210 via HIF-1α and NF-κBp50 leading to decreased STAT6 and IL-4 levels and this may contribute to the development of PE
Placental Toll-Like Receptor 3 and Toll-Like Receptor 7/8 Activation Contributes to Preeclampsia in Humans and Mice
Preeclampsia (PE) is a pregnancy-specific hypertensive syndrome characterized by excessive maternal immune system activation, inflammation, and endothelial dysfunction. Toll-like receptor (TLR) 3 activation by double-stranded RNA (dsRNA) and TLR7/8 activation by single-stranded RNA (ssRNA) expressed by viruses and/or released from necrotic cells initiates a pro-inflammatory immune response; however it is unknown whether viral/endogenous RNA is a key initiating signal that contributes to the development of PE. We hypothesized that TLR3/7/8 activation will be evident in placentas of women with PE, and sufficient to induce PE-like symptoms in mice. Placental immunoreactivity and mRNA levels of TLR3, TLR7, and TLR8 were increased significantly in women with PE compared to normotensive women. Treatment of human trophoblasts with the TLR3 agonist polyinosine-polycytidylic acid (poly I:C), the TLR7-specific agonist imiquimod (R-837), or the TLR7/8 agonist CLO97 significantly increased TLR3/7/8 levels. Treatment of mice with poly I:C, R-837, or CLO97 caused pregnancy-dependent hypertension, endothelial dysfunction, splenomegaly, and placental inflammation. These data demonstrate that RNA-mediated activation of TLR3 and TLR7/8 plays a key role in the development of PE
MicroRNAs: New Players in the Pathobiology of Preeclampsia
Our understanding of how microRNAs (miRNAs) regulate gene networks and affect different molecular pathways leading to various human pathologies has significantly improved over the years. In contrary, the role of miRNAs in pregnancy-related hypertensive disorders such as preeclampsia (PE) is only beginning to emerge. Recent papers highlight that adverse pregnancy outcomes are associated with aberrant expression of several miRNAs. Presently, efforts are underway to determine the biologic function of these placental miRNAs which can shed light on their contribution to these pregnancy-related disease conditions. The discovery that miRNAs are stable in circulation coupled with the fact that the placenta is capable of releasing them to the circulation in exosomes generates a lot of enthusiasm to use them as biomarkers. In this review, we will summarize the recent findings of our understanding of miRNA regulation in relation to PE, a hypertensive disorder of pregnancy. Particular emphasis will be given to the role of key miRNA molecules such as miR-210 and miR-155 that are known to be consistently dysregulated in women with PE
Protein Kinase CβII-Mediated Phosphorylation of Endothelial Nitric Oxide Synthase Threonine 495 Mediates the Endothelial Dysfunction Induced by FK506 (Tacrolimus)
FK506 [tacrolimus; hexadecahydro-5,19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c][1,4]oxa-azacyclotricosine-1,7,20,21(4H,23H)-tetrone] is used clinically to reduce the incidence of allograft rejection; however, chronic administration leads to endothelial dysfunction and hypertension. We have previously shown that FK506 activates Ca2+/diacylglycerol-dependent conventional protein kinase C (cPKC), which phosphorylates endothelial nitric oxide synthase (eNOS) at one of its inhibitory sites, Thr495. However, which cPKC isoform is responsible for phosphorylating eNOS Thr495 is unknown. The aim of the current study was to determine the cPKC isoform that is activated by FK506, leading to decreased endothelial function. FK506 reduced endothelium-dependent relaxation responses, yet had no effect on endothelium-independent relaxation responses in aortas from control mice. Of the various cPKC isoforms, only the administration of a PKCβII isoform-specific peptide inhibitor restored aortic relaxation responses to that of controls. In aortic endothelial cells, FK506 significantly increased PKCβII activation compared with vehicle-treated controls, and this was prevented by a PKCβII isoform-specific peptide inhibitor. In addition, a PKCβII isoform-specific peptide inhibitor prevented the increase in eNOS Thr495 phosphorylation induced by FK506. Taken together, our results indicate that βII is the cPKC isoform responsible for phosphorylating eNOS at the inhibitory site Thr495 in response to FK506. PKCβII inhibition could prove beneficial in ameliorating the endothelial dysfunction and hypertension in patients treated with FK506
Placental STAT6 and IL-4 levels are decreased significantly in P-PIC mice.
<p>A. Schematic of human <i>STAT6</i> 3′-UTR sequence targeted by miR-210. The predicted seed regions by both TargetScan and miRanda algorithms are indicated. B. Placental cell lysates from both P and P-PIC mice at gestational day 18 were subjected to immunoblot analyses using anti-STAT6 antibodies. Immunoblot analysis with an anti-β-actin antibody served as a loading control. The first lane in the immunoblot indicates the molecular weight marker. C. mRNA levels of IL-4 were determined by qRT–PCR after isolation of total RNA from placentas of both P and P-PIC mice at gestational day 18. qRT–PCR of GAPDH was used for normalization. Results are expressed as mean+SEM for 3 independent experiments. *<i>P</i><0.05 vs. P.</p
Regulation of the Anti-Inflammatory Cytokines Interleukin-4 and Interleukin-10 during Pregnancy
Inflammation mediated by both innate and adaptive immune cells is necessary for several important processes during pregnancy. Pro-inflammatory immune cell activation plays a critical role in embryo implantation, placentation, and parturition; however dysregulation of these cells can lead to detrimental pregnancy outcomes including spontaneous abortion, fetal growth restriction, maternal pathology including hypertensive disorders, or fetal and maternal death. The resolution of inflammation plays an important role throughout pregnancy and is largely mediated by immune cells that produce interleukin (IL)-4 and IL-10. The temporal and spatial aspects of reducing inflammation during pregnancy represent a complex process that if not functioning optimally can lead to persistent inflammation and pregnancy complications. In this review we examine how immune cells that produce IL-4 and IL-10 are regulated throughout pregnancy as well as the effects that reduced IL-4 and IL-10 signaling has on fetal and maternal physiology
No significant change in placental HIF-1α, NF-κB, miR-210, STAT6, and IL-4 levels in TLR3 KO P-PIC mice.
<p>A and B. Placental cell lysates from both P TLR3 KO and P-PIC TLR3 KO mice at gestational day 18 were subjected to immunoblot analyses using anti-HIF-1α and anti-NF-κB antibodies. No significant difference was noted in HIF-1α and NF-κB levels between P TLR3 KO and P-PIC TLR3 KO mice. The first lane in the immunoblot A indicates the molecular weight marker. C. Placental miR-210 levels in both P TLR3 KO and P-PIC TLR3 KO mice were determined by qRT-PCR. D. No difference was noted in placental STAT6 levels between P TLR3 KO and P-PIC TLR3 KO mice by immunoblot analysis. The first lane indicates the molecular weight marker. Because we did not observe any significant difference in STAT6 levels between WT P and TLR3 KO P mice indicating that deficiency of TLR3 in mice did not alter baseline STAT6 levels we did not include this data in Fig. 3. E. IL-4 mRNA levels were determined by qRT–PCR from placentas of both P TLR3 KO and P-PIC TLR3 KO at gestational day 18. GAPDH was used for normalization. Results are expressed as mean+SEM for 3 independent experiments. *<i>P</i><0.05 vs. P TLR3 KO.</p
Poly I:C increased HIF-1α and NF-κB which induced miR-210 leading to decreased STAT6 and IL-4 in human CTBs.
<p>A and B. CTB cells were treated with poly I:C (2 ug/ml) for 6, 24, or 48 hrs. Cell lysates were isolated and immunoblotting was performed using anti-HIF-1α and anti-NF-κB antibodies. Results are expressed as mean+SEM for 3 independent experiments. The first lane in the immunoblots in A and B indicate the molecular weight marker. C. Under the same conditions as above, miR-210 expression increased following TLR3 activation with the peak induction seen at 48 hrs as determined by qRT-PCR. D. Poly I:C treatment for 48 hrs showed the strongest down-regulation of STAT6 as determined by immunoblotting. The first and last lanes in the immunoblot indicate the molecular weight marker. E. Relative fold-change in IL-4 levels following poly I:C treatment in CTB cells. Results are expressed as mean+SEM and *<i>P</i><0.05 vs. P.</p
HIF-1α and NF-κB induced miR-210 expression in hypertensive P-PIC mice.
<p>A. Total RNA (including small RNAs) was isolated from placentas of both P and P-PIC mice at gestational day 18. miR-210 expression was subsequently determined by qRT-PCR. qRT–PCR of snoRNA 142 was used for normalization. Results are expressed as mean+SEM for 3 independent experiments. *<i>P</i><0.05 by Student’s t-test. B. Systolic blood pressures in P and P-PIC mice were measured at gestational days 0, 13, and 17 via tail-cuff plethysmography. The results are expressed as mean+SEM with 8 mice in each group. *<i>P</i><0.05 vs. P. C and D. Immunoblot analyses using anti-HIF-1α and anti-NF-κB antibodies on cell lysates prepared from placentas of P and P-PIC mice at gestational day 18. β-actin was used as a loading control. The first lane in both immunoblots indicate the molecular weight marker. Signals from 3 independent experiments were quantified and expressed as a percentage of P. The results are expressed as mean+SEM for percentage of P for 3 independent experiments. *<i>P</i><0.05 vs. P.</p